Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Nature Biotechnology

Volumn 32, Issue 10, 2014, Pages 1059-1062

  Lyon, Robert P ^a   Setter, Jocelyn R ^a   Bovee, Tim D ^a   Doronina, Svetlana O ^a   Hunter, Joshua H ^a   Anderson, Martha E ^a   Balasubramanian, Cindy L ^a   Duniho, Steven M ^a   Leiske, Chris I ^a   Li, Fu ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITION REACTIONS; ANTIBODIES; CHEMICAL REACTIONS;

ANTI-TUMOR ACTIVITIES; ANTIBODY-DRUG CONJUGATES; DIAMINOPROPIONIC ACID; ELIMINATION REACTION; INTRAMOLECULAR CATALYSIS; LINKER TECHNOLOGY; PHARMACOLOGICAL PROPERTIES; RETRO-MICHAEL REACTION;

HYDROLYSIS;

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; DIAMINO ACID; DIAMINOPROPIONIC ACID; MALEIMIDE; MALEIMIDE DERIVATIVE; THIOSUCCINIMIDE; UNCLASSIFIED DRUG; VALINE CITRULLINE 4 AMINOBENZYLMONOMETHYL AURISTATIN E; ANTIBODY; ANTIBODY CONJUGATE; EXCIPIENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; ELIMINATION REACTION; FEMALE; HODGKIN DISEASE; MICHAEL ADDITION; MOUSE; NEUTROPENIA; NONHUMAN; PH; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; HYDROLYSIS; PLASMA; SCID MOUSE;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; EXCIPIENTS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; IMMUNOCONJUGATES; MALEIMIDES; MICE; MICE, SCID; PLASMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921407368     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2968     Document Type: Article

References (30)

1. Mullard, A. Maturing antibody-drug conjugate pipeline hits 30. Nat. Rev. Drug Discov. 12, 329-332 (2013).
2. Sievers, E.L. & Senter, P.D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013).
3. Okeley, N.M., Alley, S.C. & Senter, P.D. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. Hematol. Oncol. Clin. North Am. 28, 13-25 (2014).
4. Senter, P.D. & Sievers, E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30, 631-637 (2012).
5. Peddi, P.F. & Hurvitz, S.A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 9, 319-326 (2013).
6. Hermanson, G.T. Bioconjugate Techniques. 2nd Edn. (Academic Press, San Diego, 2008).
7. Chari, R.V., Miller, M.L. & Widdison, W.C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Edn Engl. 53, 3796-3827 (2014).
8. Alley, S.C. et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19, 759-765 (2008).
9. Shen, B.Q. et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30, 184-189 (2012).
10. Baldwin, A.D. & Kiick, K.L. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug. Chem. 22, 1946-1953 (2011).
11. Ryan, C.P. et al. Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis. Chem. Commun. (Camb.) 47, 5452-5454 (2011).
12. Sassoon, I. & Blanc, V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol. Biol. 1045, 1-27 (2013).
13. Zolot, R.S., Basu, S. & Million, R.P. Antibody-drug conjugates. Nat. Rev. Drug Discov. 12, 259-260 (2013).
14. Chudasama, V.L. et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 92, 520-527 (2012).
15. Strop, P. et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20, 161-167 (2013).
16. Toda, N., Asano, S. & Barbas, C.F. 3rd rapid, stable, chemoselective labeling of thiols with Julia-Kocienski-like reagents: a serum-stable alternative to maleimide-based protein conjugation. Angew. Chem. Int. Edn Engl. 52, 12592-12596 (2013).
17. Jeffrey, S.C. et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug. Chem. 24, 1256-1263 (2013).
18. Knight, P. Hydrolysis of p-N,N'-phenylenebismaleimide and its adducts with cysteine. Biochem. J. 179, 191-197 (1979).
19. Kalia, J. & Raines, R.T. Catalysis of imido group hydrolysis in a maleimide conjugate. Bioorg. Med. Chem. Lett. 17, 6286-6289 (2007).
20. Badescu, G. et al. A new reagent for stable thiol-specific conjugation. Bioconjug. Chem. 25, 460-469 (2014).
21. Agarwal, P., van der Weijden, J., Sletten, E.M., Rabuka, D. & Bertozzi, C.R.A. Pictet-Spengler ligation for protein chemical modification. Proc. Natl. Acad. Sci. USA 110, 46-51 (2013).
22. Tian, F. et al. A general approach to site-specific antibody drug conjugates. Proc. Natl. Acad. Sci. USA 111, 1766-1771 (2014).
23. Doronina, S.O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784 (2003).
24. Francisco, J.A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-1465 (2003).
25. Lyon, R.P., Meyer, D.L., Setter, J.R. & Senter, P.D. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol. 502, 123-138 (2012).
26. Hamblett, K.J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004).
27. Sanderson, R.J. et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852 (2005).
28. Wahl, A.F. et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736-3742 (2002).
29. Dubowchik, G.M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13, 855-869 (2002).
30. Sun, M.M. et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 16, 1282-1290 (2005).